Challenges in diagnosis and management of neonatal hyperparathyroidism in a resource-limited country: A case series from a sudanese family

listen audio

Study Justification:
– Neonatal hyperparathyroidism is a rare disease with potentially life-threatening manifestations if left untreated.
– This case series is the first reported from Sudan, highlighting the need for research in resource-limited countries.
– The study emphasizes the challenges in diagnosing and managing neonatal hyperparathyroidism in such settings.
– Genetic testing is crucial for accurate diagnosis and management, especially in countries with high rates of consanguineous marriage.
Highlights:
– The case series includes three Sudanese siblings with severe symptoms of hypercalcemia, including polyuria, failure to thrive, and multiple bone fractures.
– Medical management was challenging due to the unavailability of necessary medications.
– Parathyroidectomy was necessary for all three siblings, with tissue biopsies revealing parathyroid hyperplasia.
– Genetic sequencing identified a homozygous missense mutation in two siblings, with both parents being heterozygous for the same mutation.
– The study emphasizes the importance of genetic testing and surgical intervention in managing neonatal hyperparathyroidism.
Recommendations:
– Improve access to necessary medications, such as parenteral bisphosphonates and calcimimetics, in resource-limited countries.
– Increase awareness and availability of genetic testing for accurate diagnosis and management.
– Enhance surgical capabilities and expertise for parathyroidectomy in these settings.
– Promote research and collaboration to further understand and address the challenges of neonatal hyperparathyroidism in resource-limited countries.
Key Role Players:
– Medical professionals specializing in endocrinology and pediatric surgery.
– Geneticists and genetic counselors for accurate diagnosis and counseling.
– Policy makers and government officials to allocate resources and improve healthcare infrastructure.
– Patient advocacy groups to raise awareness and support for families affected by neonatal hyperparathyroidism.
Cost Items for Planning Recommendations:
– Procurement and availability of necessary medications, including parenteral bisphosphonates and calcimimetics.
– Investment in genetic testing facilities and equipment.
– Training and education for medical professionals in endocrinology, pediatric surgery, and genetics.
– Surgical equipment and resources for parathyroidectomy procedures.
– Research funding for further studies on neonatal hyperparathyroidism in resource-limited countries.

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is moderately strong. The case series provides detailed information about three cases of neonatal hyperparathyroidism in a resource-limited country. The description includes relevant clinical information, laboratory findings, and treatment outcomes. However, the evidence could be strengthened by including more cases and providing additional details about the diagnostic process and management challenges. To improve the evidence, future studies could include a larger sample size, comparative analysis, and a discussion of potential limitations and implications for clinical practice.

Neonatal hyperparathyroidism is a rare disease caused by a homozygous inactivating mutation in the calcium sensing receptor gene. It presents early in life with life threatening manifestations of hypercalcemia, if left untreated the condition may be lethal. This is the first case series reported from Sudan. Three Sudanese siblings presented with severe symptoms of hypercalcemia in the form of polyuria, failure to thrive and multiple bone fractures. Serum calcium and parathyroid hormone levels were very high with low phosphate and normal alkaline phosphatase levels. Ultrasonography and sestamibi scan were normal and did not assist in diagnosing their condition. Medical management was a great challenge due to unavailability of medications such as parentral bisphosphonates and calcimimetics. Parathyroidectomy was inevitable. Tissue biopsies revealed parathyroid hyperplasia and no adenoma. Gene sequencing revealed a homozygous missense mutation: c 2038 C T p (Arg680Cys) in two siblings, both parents were heterozygous for the same missense mutation. Our report reflects the challenges in diagnosis and management of neonatal hyperparathyroidism in resource limited countries. We also highlight the importance of genetic testing in the diagnosis and management of such cases in countries with high rates of consanguineous marriage.

Case 1 {(1V/12), Figure 1}: a 7-month-old female presented with multiple bone fractures and was accidentally found to have hypercalcemia on routine investigations. She had a history of NICU admission for what was thought to be neonatal sepsis because of poor feeding and floppiness, chronic constipation, and failure to thrive but no history of urinary stones. Her birth was 2.8 kg. There were no dysmorphic features and her weight at presentation was 5 kg (-2.6 standard deviation (SD) below the mean for her age and sex). Parents are healthy first-degree cousins. The daughter of her maternal cousin was diagnosed with hyperparathyroidism in infancy which required parathyroidectomy. The biochemical, radiological, and histopathological findings are shown in Table 1. Her mother´s calcium level was 11.3 mg/dl (2.83 mmol/l), father´s level was 9.1 mg/dl (2.27 mmol/l). Vitamin D3 was not measured for the parents. She only showed a partial response to medical treatment of hypercalcemia, in the form of intravenous saline with furosemide 2 mg/kg/dose TDS, bisphosphonates in the form of oral alendronate 10 mg/day and calcitonin 4 IU/kg given subcutaneously every 6 hours. The lowest calcium level achieved with medical treatment was 17 mg/dl. Surgical intervention was inevitable and included total parathyroidectomy through bilateral neck incision and removal of the four parathyroid glands with re-implantation of one gland in the sternocleidomastoid muscle. Following surgery, she remained symptomatic with persistently high levels of calcium and PTH. The condition was not responsive to same medical treatment mentioned and required a second surgery to remove any remaining parathyroid tissue 8 weeks following the first surgery. Her calcium levels normalized immediately following the second surgery and after which she remained asymptomatic with normal calcium levels without any treatment. She managed to catch up normal growth for her age by the age of 36 months. family pedigree biochemical, radiological and histopathological findings in case one and two PTH: parathyroid hormone; UCCR: urinary calcium creatinine ratio Case 2 {(1V/13),(Figure 1)} a younger male sibling, presented at the age of 8 months with a history of chronic constipation, abdominal pain, polyuria, failure to thrive, and floppiness since birth. a younger male sibling, presented at the age of 8 months with a history of chronic constipation, abdominal pain, polyuria, failure to thrive, and floppiness since birth. He had no history of bone fractures nor urinary stones. There were no dysmorphic features and his weight was 6 kg (-3.5 SD). His biochemical and radiological findings are shown in Table 1. Hypercalcemia was resistant to available medical treatment in the form of intravenous saline and furosemide, oral bisphosphonates, and calcitonin. Surgical intervention was required and removal of all four parathyroid glands with reimplantation of the fourth one in the sternocleidomastoid muscle was done. Immediately following surgery, he developed hypocalcemia and required intravenous calcium then was shifted to oral calcium supplementations, 40 mg/kg/day for 6 weeks after which his calcium levels normalized. There after 6 weeks from his surgery he remained asymptomatic with normal calcium levels and required no further treatment. He managed to catch up to normal growth for his age at 30 months. Case 3 {(1V/14), (Figure 1)}: the younger sibling presented post-delivery with severe symptoms of hypercalcemia, bone fractures and respiratory distress that required ventilatory support. PTH and calcium levels were high. Management required parathyroidectomy. Further medical data was difficult to access as this patient was born abroad in Saudi Arabia (Figure 1).

N/A

Based on the provided information, here are some potential innovations that can be used to improve access to maternal health:

1. Telemedicine: Implementing telemedicine platforms can help connect healthcare providers in resource-limited countries with specialists in maternal health. This can facilitate remote consultations, diagnosis, and treatment planning, reducing the need for patients to travel long distances for specialized care.

2. Mobile health (mHealth) applications: Developing mobile applications that provide educational resources, reminders for prenatal care appointments, and access to teleconsultations can improve maternal health outcomes. These apps can also provide personalized health information and track maternal health indicators, such as blood pressure and weight gain.

3. Training and capacity building: Investing in training programs for healthcare providers in resource-limited countries can enhance their skills and knowledge in managing maternal health conditions. This can include specialized training in diagnosing and managing rare conditions like neonatal hyperparathyroidism.

4. Supply chain management: Improving the availability and accessibility of essential medications and medical supplies, such as parentral bisphosphonates and calcimimetics, is crucial for effective management of maternal health conditions. Implementing efficient supply chain management systems can help ensure a steady supply of these medications in resource-limited settings.

5. Genetic testing and counseling: Promoting the use of genetic testing in diagnosing and managing rare conditions can improve maternal and neonatal health outcomes. Establishing genetic counseling services can help families understand the implications of genetic conditions and make informed decisions about family planning.

6. Collaboration and partnerships: Encouraging collaboration between local healthcare providers, international organizations, and academic institutions can foster knowledge sharing, resource allocation, and research efforts to address maternal health challenges in resource-limited countries.
AI Innovations Description
Based on the provided description, here is a recommendation that can be developed into an innovation to improve access to maternal health:

Develop a mobile application or online platform that provides information and resources on neonatal hyperparathyroidism, including diagnosis, management, and available treatments. This platform should be accessible in resource-limited countries and should include features such as:

1. Diagnostic tools: Provide guidelines and algorithms for healthcare providers to accurately diagnose neonatal hyperparathyroidism, even in the absence of advanced imaging techniques.

2. Treatment options: Offer information on available medications, such as parenteral bisphosphonates and calcimimetics, and provide guidance on their administration and dosage.

3. Surgical interventions: Provide detailed instructions and resources for healthcare providers on performing parathyroidectomy, including surgical techniques and post-operative care.

4. Genetic testing: Highlight the importance of genetic testing in the diagnosis and management of neonatal hyperparathyroidism, particularly in countries with high rates of consanguineous marriage. Include information on how to access genetic testing services and interpret the results.

5. Patient education: Develop educational materials for parents and caregivers, explaining the condition, its symptoms, and the importance of early diagnosis and treatment. Provide resources for managing the condition at home, including information on diet and lifestyle modifications.

6. Telemedicine support: Incorporate telemedicine capabilities into the platform, allowing healthcare providers in resource-limited areas to consult with specialists and receive guidance on diagnosis and management.

By developing this mobile application or online platform, healthcare providers in resource-limited countries will have access to up-to-date information and resources on neonatal hyperparathyroidism. This will improve their ability to diagnose and manage the condition, ultimately leading to better outcomes for affected infants and their families.
AI Innovations Methodology
To improve access to maternal health, here are some potential recommendations:

1. Telemedicine: Implementing telemedicine services can help overcome geographical barriers and provide remote access to healthcare professionals. This can be particularly beneficial in resource-limited areas where there may be a shortage of maternal health specialists.

2. Mobile health (mHealth) applications: Developing mobile applications that provide information, education, and reminders for pregnant women can improve access to maternal health services. These apps can also include features like appointment scheduling, medication reminders, and access to teleconsultations.

3. Community health workers: Training and deploying community health workers can help bridge the gap between healthcare facilities and pregnant women in remote areas. These workers can provide basic prenatal care, education, and referrals to appropriate healthcare facilities when needed.

4. Transportation support: Lack of transportation can be a significant barrier to accessing maternal health services. Providing transportation support, such as subsidized or free transportation services, can help pregnant women reach healthcare facilities for prenatal care, delivery, and postnatal care.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define the target population: Identify the specific population that will benefit from the recommendations, such as pregnant women in a particular region or community.

2. Collect baseline data: Gather data on the current access to maternal health services in the target population. This can include information on the number of healthcare facilities, distance to the nearest facility, availability of healthcare professionals, and utilization rates of maternal health services.

3. Define indicators: Determine the key indicators that will be used to measure the impact of the recommendations. This can include indicators such as the number of prenatal visits, percentage of women receiving skilled birth attendance, and maternal mortality rates.

4. Simulate the impact: Using the collected data and indicators, simulate the impact of implementing the recommendations. This can be done through mathematical modeling or computer simulations that take into account factors such as population size, geographical distribution, and resource availability.

5. Analyze the results: Evaluate the simulated impact of the recommendations on improving access to maternal health. This can include assessing changes in the indicators defined in step 3 and comparing them to the baseline data.

6. Refine and iterate: Based on the analysis of the results, refine the recommendations and simulation methodology if necessary. Iterate the process to further optimize the impact on improving access to maternal health.

By following this methodology, policymakers and healthcare providers can gain insights into the potential impact of implementing specific recommendations and make informed decisions to improve access to maternal health.

Share this:
Facebook
Twitter
LinkedIn
WhatsApp
Email